Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 24, 2014 10:40 AM EDT
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $111.00 (from $106.00) following better-than-expected Q2 results and outlook.
Schimmer commented, "Yet again, GILD easily surpassed top/bottom line numbers but contracted LT growth... More
July 24, 2014 6:40 AM EDT
BMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following Q2 results.
Birchenough comments, "With SOVALDI continuing to set sales records on a background of incomplete insurance coverage in the U.S.,... More
July 23, 2014 4:48 PM EDT
Gilead Sciences (NASDAQ: GILD) said about 9,000 Hep C patients have been cured with Sovaldi to date
...
More
July 23, 2014 4:04 PM EDT
Gilead Sciences (NASDAQ: GILD) trading halted with news pending.
...
More
